Torrance, CA – Kowa Optimed, Inc., is part of a multi-faceted global company providing products and services to diverse markets, recently announced that they have received 501(k) approval from the U.S. Food and Drug Administration (FDA) for the marketi…
Category: News
Kowa Optimed Receives 510(k) Clearance For NonmydT WX3D
Torrance, CA – Kowa Optimed, Inc., is part of a multi-faceted global company providing products and services to diverse markets, recently announced that they have received 501(k) approval from the U.S. Food and Drug Administration (FDA) for the marketi…
Kowa Optimed Receives 510(k) Clearance For NonmydT WX3D
Torrance, CA – Kowa Optimed, Inc., is part of a multi-faceted global company providing products and services to diverse markets, recently announced that they have received 501(k) approval from the U.S. Food and Drug Administration (FDA) for the marketi…
Effort to Repeal 1099 Requirement Is ‘Chaotic’
Congress has been trying to eliminate an onerous paperwork requirement of the new healthcare reform law since 2009 but cannot agree on how to make up the revenue it will lose in the process. Medscape Medical News
Risk for Ocular Complications From Topical Corticosteroids
The risk for glaucoma and cataracts is evaluated in patients with atopic dermatitis who use topical corticosteroids on the face. Medscape Dermatology
Illuminating Neuron Activity
All our daily activities, from driving to work to solving a crossword puzzle, depend on signals carried along the body’s vast network of neurons. Propagation of these signals is, in turn, dependent on myriad small molecules within nerve cells – recepto…
Method Of Clustered Gene Expression Analysis May Lead To Glaucoma Prevention
Glaucoma is the second-most common cause of blindness in the US, and occurs due to loss of retinal ganglion cells and degeneration of the optic nerve. Although it is known that high levels of pressure within the eye predispose individuals to the develo…
News From The Journal Of Clinical Investigation: March 7, 2011
CARDIOVASCULAR DISEASE: Tie-ing up loose ends: new hope for atherosclerosis therapy? Atherosclerosis is a buildup of fatty deposits in the walls of blood vessels that can predispose patients to heart attacks. Notably, these deposits most often form at …
Advances in Keratoconus Treatment
What is keratoconus, and what are some of the new and advanced methods for treating it? Expert Review of Ophthalmology
Clustering Gene Expression Changes Reveals Pathways Toward Glaucoma Prevention
Glaucoma is the second-most common cause of blindness in the US, and occurs due to loss of retinal ganglion cells and degeneration of the optic nerve. Although it is known that high levels of pressure within the eye predispose individuals to the develo…
NICE Consults On A New Drug To Treat Diabetic Macular Oedema
In draft guidance issued yesterday, NICE has not recommended ranibizumab (Lucentis, Novartis) for treating diabetic macular oedema (DMO).
Additional Support For Ophthalmic Applications For Laser Technology Using The Company’s Er,Cr:YSGG Waterlase Technology
BIOLASE Technology, Inc. (NASDAQ: BLTI), the World’s leading dental laser manufacturer and distributor, today announced that the U.S. Patent and Trademark Office has issued BIOLASE a new patent covering the use of its laser technologies for treating va…
NICE Consults On A New Drug To Treat Diabetic Macular Oedema
In draft guidance issued yesterday, NICE has not recommended ranibizumab (Lucentis, Novartis) for treating diabetic macular oedema (DMO).
Clustering Gene Expression Changes Reveals Pathways Toward Glaucoma Prevention
Glaucoma is the second-most common cause of blindness in the US, and occurs due to loss of retinal ganglion cells and degeneration of the optic nerve. Although it is known that high levels of pressure within the eye predispose individuals to the develo…
Additional Support For Ophthalmic Applications For Laser Technology Using The Company’s Er,Cr:YSGG Waterlase Technology
BIOLASE Technology, Inc. (NASDAQ: BLTI), the World’s leading dental laser manufacturer and distributor, today announced that the U.S. Patent and Trademark Office has issued BIOLASE a new patent covering the use of its laser technologies for treating va…
Research Fraud: An Editor’s Responsibility?
In the wake of the autism controversy, pediatric psychiatrist and journal editor Dr. Fred Volkmar discusses the roles and responsibilities of editors in vetting the information they publish. Medscape Psychiatry & Mental Health
Aerie Pharmaceuticals closes $30 million Series B financing
Aerie Pharmaceuticals, Inc, a biotechnology company focused on the discovery and development of medical innovations in ophthalmology, today announced the closing of a $30 million Series B financing.
Changes In IOP After Cataract Removal Reported For Observation Group Of The OHTS
Cataract surgery lowers IOP by 18% in patients with untreated ocular hypertension, a surgeon reported, giving results derived from the Ocular Hypertension Treatment Study.
Changes In IOP After Cataract Removal Reported For Observation Group Of The OHTS
Cataract surgery lowers IOP by 18% in patients with untreated ocular hypertension, a surgeon reported, giving results derived from the Ocular Hypertension Treatment Study.
NICE Consults On A New Drug To Treat Diabetic Macular Oedema
In draft guidance issued yesterday, NICE has not recommended ranibizumab (Lucentis, Novartis) for treating diabetic macular oedema (DMO). This draft guidance has been issued for consultation. NICE has not yet issued final guidance to the NHS…